These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30545922)

  • 1. Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
    Delage L; Manzoni D; Quinquenet C; Fontaine J; Maarek A; Chabane K; Mosnier I; Hayette S; Callet-Bauchu E; Grange B; Plesa A; Sujobert P
    Haematologica; 2019 Mar; 104(3):e114-e116. PubMed ID: 30545922
    [No Abstract]   [Full Text] [Related]  

  • 2. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
    Shimazu Y; Nohgawa M
    J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
    [No Abstract]   [Full Text] [Related]  

  • 3. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
    Kari EJM; Kuusisto MEL; Honkavaara P; Hakalahti A; Haapasaari KM; Bloigu R; Karihtala P; Teppo HR; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O
    Eur J Haematol; 2020 Aug; 105(2):156-163. PubMed ID: 32248578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
    Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S
    Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.
    Arakaki H; Nakazato T; Osada Y; Ito C; Aisa Y; Mori T
    Ann Hematol; 2017 Jul; 96(7):1225-1226. PubMed ID: 28508175
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
    Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
    Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
    [No Abstract]   [Full Text] [Related]  

  • 8. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma.
    Arima H; Maruoka H; Nasu K; Tabata S; Kurata M; Matsushita A; Imai Y; Takahashi T; Ishikawa T
    Leuk Lymphoma; 2013 Dec; 54(12):2645-53. PubMed ID: 23566159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 11. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.
    Zhang JY; Zhang PP; Zhou WP; Yu JY; Yao ZH; Chu JF; Yao SN; Wang C; Lone W; Xia QX; Ma J; Yang SJ; Liu KD; Dong ZG; Guo YJ; Smith LM; McKeithan TW; Chan WC; Iqbal J; Liu YY
    Clin Cancer Res; 2019 Jul; 25(13):4168-4178. PubMed ID: 30824586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.
    Oki Y; Ewer MS; Lenihan DJ; Fisch MJ; Hagemeister FB; Fanale M; Romaguera J; Pro B; Fowler N; Younes A; Astrow AB; Huang X; Kwak LW; Samaniego F; McLaughlin P; Neelapu SS; Wang M; Fayad LE; Durand JB; Rodriguez MA
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):152-8. PubMed ID: 25445468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravascular large B-cell lymphoma--a diagnostic dilemma.
    Ramkumar B; Hutchison R; Khadim H; Gajra A
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):e18-21. PubMed ID: 24060286
    [No Abstract]   [Full Text] [Related]  

  • 15. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
    Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
    Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
    Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
    Bolshinsky M; Nabhan C
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):655-661. PubMed ID: 27693134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
    Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
    Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Lymphoma of Liver-a Rare Space-Occupying Lesion.
    Patkar S; Dutt K; Shah A; Sengar M; Goel M
    J Gastrointest Cancer; 2020 Sep; 51(3):1057-1060. PubMed ID: 32333249
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.